Celldex Therapeutics, INC

Celldex Therapeutics announces the planned retirement of CFO Sam Martin, effective March 31, 2027, with a search for his successor underway.

Celldex Therapeutics stockholders approved the election of directors and an increase of 3.4 million shares to the 2021 Omnibus Equity Incentive Plan.

Celldex Therapeutics has priced an underwritten public offering of 10,345,000 shares of common stock at $29.00 per share to raise approximately $282 million in net proceeds.

Celldex Therapeutics announced the early completion of enrollment for its Phase 3 CSU studies, with topline data expected in Q4 2026, alongside increased R&D expenses and a higher net loss for 2025.

Celldex Therapeutics announced positive Phase 2 clinical data for barzolvolimab in chronic urticarias and CDX-622, alongside Q3 2025 financial results and a new Chief Commercial Officer.

Celldex Therapeutics announced that its Phase 2 study of Barzolvolimab in Eosinophilic Esophagitis met its primary endpoint of mast cell depletion but failed to show clinical improvement, leading to a halt in EoE development.

Celldex Therapeutics reports Q1 2026 results, highlighting significant progress in barzolvolimab development for urticaria and other conditions, alongside increased R&D spending.

Celldex Therapeutics reported increased net losses in Q3 2025 due to higher R&D expenses for barzolvolimab, while maintaining sufficient liquidity through 2027 and advancing multiple clinical programs.

Celldex Therapeutics reports increased net loss driven by higher R&D expenses for its lead drug barzolvolimab, while maintaining strong liquidity and advancing multiple clinical programs.

Celldex Therapeutics reported a net loss of $53.8 million for Q1 2025, driven by increased R&D spending as it advances its barzolvolimab program.

Celldex Therapeutics reports a net loss of $110.8 million for the first nine months of 2024, while highlighting progress in its clinical programs, particularly with barzolvolimab.

Celldex Therapeutics reports a net loss of $68.7 million for the first half of 2024, while advancing its clinical programs, particularly barzolvolimab, across multiple indications.

Celldex Therapeutics' 2025 annual report details significant clinical advancements for Barzolvolimab and CDX-622, alongside executive compensation updates and financial performance.

Celldex Therapeutics' 10-K filing summarizes the company's focus on developing therapeutic antibodies for inflammatory, allergic, and autoimmune diseases, with key updates on its clinical programs and financial status.

Celldex Therapeutics announced positive results from its Phase 2 study of barzolvolimab in chronic spontaneous urticaria and is planning Phase 3 trials.

Teri Lawver, SVP & Chief Commercial Officer at Celldex Therapeutics, was granted 90,000 incentive stock options.

Celldex Therapeutics reports the grant of incentive stock options to SVP & General Counsel Freddy A. Jimenez.

Diane C. Young, SVP and Chief Medical Officer of Celldex Therapeutics, was granted incentive stock options for 57,000 shares.

Celldex Therapeutics reports the grant of incentive stock options to SVP of Regulatory Affairs, Margo Heath-Chiozzi.

Celldex Therapeutics SVP and CFO, Samuel Bates Martin, was granted stock options for 93,000 shares of common stock.

Celldex Therapeutics reports an executive, Sarah Cavanaugh, received an incentive stock option grant for 95,000 shares.

Celldex Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 25, 2026, to elect directors, ratify auditors, and approve equity plan amendments.

Celldex Therapeutics is asking stockholders to approve an amendment to its 2021 Omnibus Equity Incentive Plan, increasing the number of shares available for issuance by 2,000,000 to a total of 9,500,000, plus any unused shares from the 2008 plan.

Celldex Therapeutics is holding its annual meeting on June 13, 2024, to vote on key proposals including the election of directors, ratification of the auditor, an amendment to the equity incentive plan, and executive compensation.

Kynam Capital Management, LP, along with its GP and principal Yue Tang, has reported a 6.78% beneficial ownership of Celldex Therapeutics, Inc. common stock as of June 30, 2026.

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 6.0% of Celldex Therapeutics' common stock as of June 30, 2026.

Kynam Capital Management, LP has reported an 8.77% beneficial ownership stake in Celldex Therapeutics, Inc. via a Schedule 13G filing.

Bellevue Group AG and its subsidiary have filed an exit notice after reducing their stake in Celldex Therapeutics below the 5% reporting threshold.

State Street Corporation has reported beneficial ownership of 2,804,168 shares, representing 4.2% of the outstanding common stock of Celldex Therapeutics, as of March 31, 2026.

FMR LLC, through its affiliates, has reported beneficial ownership of 5.6% of Celldex Therapeutics Inc.'s common stock as of March 31, 2026.